瑞博生物于2007年由资深海归博士和国内专家团队创立，致力于自主知识产权的小核酸药物研发，以及在全球范围内开展临床项目研发及商业化
Location: China
Investors 2
| Date | Name | Website |
| 13.05.2024 | Pan Lin In... | panlincap.... |
| - | SDIC Fund ... | sdicfund.c... |
Mentions in press and media 4
| Date | Title | Description |
| 11.02.2026 | Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH | SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced that they have entere... |
| 09.01.2026 | Ribo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock Exchange | HONG KONG, Jan. 9, 2026 /PRNewswire/ -- Ribo Life Science Co., Ltd. ("Ribo" or the "Company", stock code: 06938.HK), a leading company in small interfering RNA (siRNA) therapeutics, today successfully listed on the Main ... |
| 24.10.2025 | Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection | BEIJING and GOTHENBURG, Sweden, Oct. 24, 2025 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to R... |
| - | Suzhou Ribo Life Science | “Suzhou Ruibo Biological Technology Co., Ltd.” |